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6% and estimated continuation rate of 56% and 65% af-
ter 5 years. Sensitivity analysis was performed on OC
cost using the lowest and highest costs from the RAMQ
list. Discounting was performed at 0%, 3% and 5% over
65 time-periods (13 cycles 	 5 years) for OC. No dis-
count rate was applied to Mirena since acquisition cost is
paid once at treatment start. RESULTS: The mean cost of
an OC is determined to be $11 per cycle, while drug ac-
quisition cost of Mirena is $290. All scenarios favour
Mirena. With a 5% discount rate, Mirena offered a mean
saving of $346 over 5 years. When the pharmacist’s dis-
pensing fee was included Mirena offered a mean saving
of $750. In real life conditions, with a 5% discount rate,
the use of Mirena resulted in a mean saving of at least
30% (i.e., between $194 and $221). CONCLUSION:
Mirena represents a less expensive alternative to long-
term contraception when compared to OC and this, in all
proposed scenarios.
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OBJECTIVES: To describe erectile dysfunction (ED) pa-
tient demographics, comorbidities, treatment seeking be-
havior, and patient-reported use and outcomes of ther-
apy. METHODS: A self-administered questionnaire was
developed and pilot tested. The final survey instrument
included selected demographics, questions regarding
when patients first experienced ED symptoms, when pa-
tients first sought treatment for ED, patients’ experience
with ED treatments, patients’ rating of how well a partic-
ular ED therapy worked, and comorbid conditions. Pa-
tients evaluated their experience with ED therapies on a
Likert-type scale. RESULTS: During May and June of
1997, 285 questionnaires were given to patients while
they waited to see their urologist for ED treatment. A to-
tal of 59.4 percent (n  168) of respondents (n  283)
listed “Caucasian, White” as their race. Age of the survey
respondents ranged from 31 to 82 years with a mean age
of 59.5 years (sd  11.2). A total of 27.1 percent of sur-
vey respondents completed 4 years or more of college. A
total of 31.4 percent of respondents reported 1996
household income of $30,001–$50,000. A total of 58.1
percent (n  165) of the respondents listed “Married/
long-term partner” as their marital status. A total of 76.5
percent (n  218) of respondents reported currently be-
ing treated by a physician for health problems in addition
to ED. Respondents reported a mean of 2.9 years (sd 
5.1 years, range 1 year to 34 years) between first no-
ticing the symptoms of ED and seeking professional med-
ical treatment for those symptoms. A total of 239
(83.9%) respondents reported having tried at least one
therapy option to treat their ED. The ED therapy men-
tioned most often was “an injectable drug” with a mean
rating of 3.8 (sd  1.2). CONCLUSION: This multi-site,
prospective study gives insight into patient demograph-
ics, comorbidities, experience with ED and its treatment
and allows a better understanding of therapy health out-
comes for this important medical condition.
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BACKGROUND: As of December 1 2000, the Province
of British Columbia launched a program of expanded ac-
cess to emergency contraceptive pills (ECPs) authorizing
pharmacists with special training to provide ECPs to
women without a prescription from their physicians. OB-
JECTIVES: To determine whether the expanded access
program (EAP) will increase the utilization of ECPs and
reduce pregnancy and abortion rates among women in
B.C. METHODS: This research utilizes a province-wide
prescription database (PharmaNet) that documents pre-
scription transactions for all residents. PharmaNet data
will be linked, in a manner insuring researchers are
blinded to patient identity, to information in other pro-
vincial health-care databases including physician visits,
hospitalizations, and birth and abortion records. Data for
all women with an index prescription for an ECP from a
pharmacist or a physician for the 2-year period prior to
and for the 2-year period after initiation of the EAP will
be included in the analyses. RESULTS: Four weeks after
the program launch, 50% of the province’s 2400 phar-
macists have been certified and half of those are regis-
tered providers. Currently, 340 of the province’s 760
community pharmacies have one or more pharmacists
certified and registered to prescribe ECPs. To date, 316
patients (mean age 26 years; range, 15 to 48) have re-
ceived pharmacist-initiated ECPs in 19 of the province’s
20 health regions; 58% of the pharmacist-initiated ECP
prescriptions occurred on weeknights or weekends; the
average interval between unprotected intercourse and ar-
rival in the pharmacy has been 24 hours; and 53% of the
women stated that the reason for need was due to birth
control failure. At time of presentation, these data will be
updated for the first five months of this study. CON-
CLUSIONS: Despite limited publicity to date, participa-
tion by pharmacists and access by women have been no-
table during the first four weeks of the program.
